CLINICAL TRIALS RECRUITMENT AND RETENTION Clinical Trials 2014; 11: 328–335 Increasing Asian American participation in

Background Asian Americans are underrepresented in clinical trials, but little is known about the factors that contribute to clinical trial participation in this population. Purpose The purpose of this study was to identify knowledge, barriers, facilitators, and cultural influences on participating in clinical trials among three Asian American ethnic groups. Concurrently, we sought to identify mechanisms and messages to facilitate dissemination of information and to identify strategies to promote clinical trial participation in this population. Methods Eight focus groups were conducted (n = 103) with Chinese (four groups), Korean (two groups), and Vietnamese (two groups) Americans. Each group was conducted with a moderator and a translator using a standardized guide. Results Participants discuss the benefits of contributing to science, future genera-tions, and their families by being in clinical trials. Some participants think clinical trials would give hope to those with terminal illnesses. A doctor’s recommendation, being sick, and needing more options for treatment are motivators for Asian Ameri-cans. Having some guarantee of treatment effectiveness and lack of side effects facil-itates participation. Cultural or religious beliefs are not believed to prevent clinical trial participation. Limitations This qualitative, two-site study included three Asian American ethnic groups and is not meant to establish prevalence of beliefs. Conclusion Asian Americans need more information about clinical trials and their benefits to science and the larger community. Health-care providers can play pivotal roles in enhancing recruitment of Asian Americans. Basing recruitment goals on per-centage representation in most US geographic areas does not provide sufficient numbers to allow for analysis of minorities like Asian American groups. The discov-ery of important group-specific harms and benefits depends on greater participation of racial/ethnic subgroups. Clinical Trials 2014; 11: 328–335